![](https://medcitynews.com/wp-content/uploads/sites/7/2024/07/Dan-Mandell-Headshot.jpg)
Aiming to Top Amgen in Gout, Startup GRObio Gets $60M to Enter the Clinic
For gout pain that does not respond to conventional therapies, patients’ only remaining option is a drug from Amgen. But this biologic medicine introduces the same problem facing every therapeutic protein: The body can see the engineered protein as foreign …